What type of study is this?

This is a Quantitative Study study.

September 19, 2025Open Access

Balancing Innovation, Access, and Equity in Drug Pricing: Comparative Institutional Lessons for Advancing Universal Health Coverage

View Full Paper

Ask AI

Bookmark

Authors

Comparative analysis reveals drug pricing strategies impact cost, innovation, and access in health systems.

The MFN model provides short-term savings but may stifle innovation and outcome-based reimbursement, especially in fragmented systems.
In the UK, centralized institutions like NICE achieve significant pricing alignment and access to medicines, promoting equity.
Canada enforces price controls but lacks value-based principles and risk-sharing mechanisms, limiting effective access to drugs.
Achieving Universal Health Coverage requires tailored institutional designs balancing equity, innovation, and feasibility.

Adegoke et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark